Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors.

ABSTRACT:

Background

Antiangiogenic-targeting agents have low response rates in patients with nonpancreatic neuroendocrine tumors (NETs). Nintedanib is an oral antiangiogenic agent that has inhibitory effects on the fibroblast growth factor receptor, which is highly expressed in NETs. The authors hypothesized that nintedanib would be active in patients with nonpancreatic NETs.

Methods

Patients with advanced, grade 1 or 2, nonpancreatic NETs who were receiving a stable dose of somatostatin analogue were enrolled. Nintedanib was administered at a dose of 200 mg twice daily in 28-day cycles. The primary endpoint was progression-free survival (PFS) at 16 weeks.

Results

Thirty-two patients were enrolled, and 30 were evaluable for the primary outcome. Most had radiographic disease pr

SUBMITTER: Iyer RV 

PROVIDER: S-EPMC8396074 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature